Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment

References

• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13:63-79; PMID:24336504; http://dx.doi.org/10.1038/nrd4161
   PubMed Web of Science ®Google Scholar
• Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 2015; 12:445-64; PMID:25850553; http://dx.doi.org/10.1038/nrclinonc.2015.61
   PubMed Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014; 94:1287-312; PMID:25287865; http://dx.doi.org/10.1152/physrev.00005.2014
   PubMed Web of Science ®Google Scholar
• Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013; 15:637-46; PMID:23708000; http://dx.doi.org/10.1038/ncb2756
   PubMed Web of Science ®Google Scholar
• Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474:179-83; PMID:21654799; http://dx.doi.org/10.1038/nature10137
   PubMed Web of Science ®Google Scholar
• Du X, Yu A, Tao W. The non-canonical Hippo/Mst pathway in lymphocyte development and functions. Acta Biochim Biophys Sin (Shanghai) 2015; 47:60-4; PMID:25487919; http://dx.doi.org/10.1093/abbs/gmu112
   PubMed Web of Science ®Google Scholar
• Maugeri-Saccà M, Barba M, Pizzuti L, Vici P, Di Lauro L, Dattilo R, Vitale I, Bartucci M, Mottolese M, De Maria R. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Rev Mol Med 2015; 17:e14; PMID:26136233; http://dx.doi.org/10.1017/erm.2015.12
   PubMed Web of Science ®Google Scholar
• Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget 2014; 5:9619-25; PMID:25294813; http://dx.doi.org/10.18632/oncotarget.2449
   PubMed Web of Science ®Google Scholar
• Lehn S, Tobin NP, Sims AH, Stål O, Jirström K, Axelson H, Landberg G. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. BMC Cancer 2014; 14:119; PMID:24559095; http://dx.doi.org/10.1186/1471-2407-14-119
   PubMed Web of Science ®Google Scholar
• Díaz-Martín J, López-García MÁ, Romero-Pérez L, Atienza-Amores MR, Pecero ML, Castilla MÁ, Biscuola M, Santón A, Palacios J. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer 2015; 22:443-54; PMID:25870251; http://dx.doi.org/10.1530/ERC-14-0456
   PubMed Web of Science ®Google Scholar
• Xiao H, Wu L, Zheng H, Li N, Wan H, Liang G, Zhao Y, Liang J. Expression of Yes-associated protein in cervical squamous epithelium lesions. Int J Gynecol Cancer 2014; 24:1575-82; PMID:25304677; http://dx.doi.org/10.1097/IGC.0000000000000259
   PubMed Web of Science ®Google Scholar
• Liu T, Liu Y, Gao H, Meng F, Yang S, Lou G. Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. Int J Gynecol Cancer 2013; 23:735-42; PMID:23502453; http://dx.doi.org/10.1097/IGC.0b013e31828c8619
   PubMed Web of Science ®Google Scholar
• He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med 2015; 7:1426-49; PMID:26417066; http://dx.doi.org/10.15252/emmm.201404976
   PubMed Web of Science ®Google Scholar
• Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, Park NH, Song YS, Behtash N, Kamura T et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 2013; 39:115-24; PMID:23084091; http://dx.doi.org/10.1016/j.ejso.2012.09.003
   PubMed Web of Science ®Google Scholar
• Landoni F, Sartori E, Maggino T, Zola P, Zanagnolo V, Cosio S, Ferrari F, Piovano E, Gadducci A. Is there a role for postoperative treatment in patients with stage Ib2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. Gynecol Oncol 2014; 132:611-7; PMID:24342439; http://dx.doi.org/10.1016/j.ygyno.2013.12.010
   PubMed Web of Science ®Google Scholar
• Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis. J Cancer Res Clin Oncol 2013; 139:1887-98; PMID:24022086; http://dx.doi.org/10.1007/s00432-013-1509-y
   PubMed Web of Science ®Google Scholar
• Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2010;(1):CD007406; PMID:20091632; http://dx.doi.org/10.1002/14651858.CD007406.pub2
   PubMedGoogle Scholar
• Gadducci A, Sartori E, Maggino T, Zola P, Cosio S, Zizioli V, Lapresa M, Piovano E, Landoni F. Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: an Italian multicenter retrospective study (CTF Study). Gynecol Oncol 2013; 131:640-4; PMID:24096111; http://dx.doi.org/10.1016/j.ygyno.2013.09.029
   PubMed Web of Science ®Google Scholar
• Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147:759-72; PMID:22078877; http://dx.doi.org/10.1016/j.cell.2011.09.048
   PubMed Web of Science ®Google Scholar
• Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2015; 34:681-90; PMID:24531710; http://dx.doi.org/10.1038/onc.2014.5
   PubMed Web of Science ®Google Scholar
• Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005; 18:447-59; PMID:15893728; http://dx.doi.org/10.1016/j.molcel.2005.04.008
   PubMed Web of Science ®Google Scholar
• Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11:11-23; PMID:12535517; http://dx.doi.org/10.1016/S1097-2765(02)00776-1
   PubMed Web of Science ®Google Scholar
• Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY, Shao ZM. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 2013; 19:1389-99; PMID:23340296; http://dx.doi.org/10.1158/1078-0432.CCR-12-1959
   PubMed Web of Science ®Google Scholar
• Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006; 103:12405-10; PMID:16894141; http://dx.doi.org/10.1073/pnas.0605579103
   PubMed Web of Science ®Google Scholar
• Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11:1444-50; PMID:19935651; http://dx.doi.org/10.1038/ncb1993
   PubMed Web of Science ®Google Scholar
• Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 2012; 109:E2441-50; PMID:22891335; http://dx.doi.org/10.1073/pnas.1212021109
   PubMed Web of Science ®Google Scholar
• Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 2012; 18:1511-7; PMID:23001183; http://dx.doi.org/10.1038/nm.2940
   PubMed Web of Science ®Google Scholar
• Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 2010; 18:300-8; PMID:20159599; http://dx.doi.org/10.1016/j.devcel.2009.12.011
   PubMed Web of Science ®Google Scholar
• Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013; 154:1342-55; PMID:24012335; http://dx.doi.org/10.1016/j.cell.2013.08.025
   PubMed Web of Science ®Google Scholar
• Boggiano JC, Vanderzalm PJ, Fehon RG. Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev Cell 2011; 21:888-95; PMID:22075147; http://dx.doi.org/10.1016/j.devcel.2011.08.028
   PubMed Web of Science ®Google Scholar
• Huang HL, Wang S, Yin MX, Dong L, Wang C, Wu W, Lu Y, Feng M, Dai C, Guo X et al. Par-1 regulates tissue growth by influencing hippo phosphorylation status and hippo-salvador association. PLoS Biol 2013; 11:e1001620; PMID:23940457; http://dx.doi.org/10.1371/journal.pbio.1001620
   Google Scholar
• Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG, Rossant J, Wrana JL. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev Cell 2010; 19:831-44; PMID:21145499; http://dx.doi.org/10.1016/j.devcel.2010.11.012
   PubMed Web of Science ®Google Scholar
• Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286:7018-26; PMID:21224387; http://dx.doi.org/10.1074/jbc.C110.212621
   PubMed Web of Science ®Google Scholar
• Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell 2011; 144:782-95; PMID:21376238; http://dx.doi.org/10.1016/j.cell.2011.02.031
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150:780-91; PMID:22863277; http://dx.doi.org/10.1016/j.cell.2012.06.037
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014; 16:357-66; PMID:24658687; http://dx.doi.org/10.1038/ncb2936
   PubMed Web of Science ®Google Scholar
• Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J 2015; 34:1349-70; PMID:25796446; http://dx.doi.org/10.15252/embj.201490379
   PubMed Web of Science ®Google Scholar
• Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 2014; 158:157-70; PMID:24976009; http://dx.doi.org/10.1016/j.cell.2014.06.013
   PubMed Web of Science ®Google Scholar
• Dong Y, Du X, Ye J, Han M, Xu T, Zhuang Y, Tao W. A cell-intrinsic role for Mst1 in regulating thymocyte egress. J Immunol 2009; 183(6):3865-72; PMID:19692642; http://dx.doi.org/10.4049/jimmunol.0900678
   PubMed Web of Science ®Google Scholar
• Nehme NT, Pachlopnik Schmid J, Debeurme F, André-Schmutz I, Lim A, Nitschke P, Rieux-Laucat F, Lutz P, Picard C, Mahlaoui N et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012; 119:3458-68. Dec 14; PMID:22174160; http://dx.doi.org/10.1182/blood-2011-09-378364
   PubMed Web of Science ®Google Scholar
• Katagiri K, Katakai T, Ebisuno Y, Ueda Y, Okada T, Kinashi T. Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. EMBO J 2009; 28:1319-31; PMID:19339990; http://dx.doi.org/10.1038/emboj.2009.82
   PubMed Web of Science ®Google Scholar
• Katagiri K, Imamura M, Kinashi T. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol 2006; 7:919-28; PMID:16892067; http://dx.doi.org/10.1038/ni1374
   PubMed Web of Science ®Google Scholar
• Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, Gertz EM, Schambach A, Kreipe HH, Pfeifer D et al. The phenotype of human STK4 deficiency. Blood 2012; 119:3450-7; PMID:22294732; http://dx.doi.org/10.1182/blood-2011-09-378158
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-71; PMID:25214542; http://dx.doi.org/10.1093/annonc/mdu450
   PubMed Web of Science ®Google Scholar
• Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005; 23:4137-45; PMID:15961761; http://dx.doi.org/10.1200/JCO.2005.04.172
   PubMed Web of Science ®Google Scholar
• Bria E, Milella M, Sperduti I, Alessandrini G, Visca P, Corzani F, Giannarelli D, Cerasoli V, Cuppone F, Cecere FL et al. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer 2009; 66:365-71; PMID:19327866; http://dx.doi.org/10.1016/j.lungcan.2009.02.024
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003; 56:441-7; PMID:12812818; http://dx.doi.org/10.1016/S0895-4356(03)00047-7
   PubMed Web of Science ®Google Scholar